TTFACTOR SRL

Their core work

TTFACTOR is a Milan-based private company specializing in technology transfer and commercialization support for life science research. They consistently appear as a third-party service provider in ERC Proof of Concept grants, helping academic researchers translate molecular biology discoveries into viable products or therapies. Their project portfolio spans cancer therapy (DDRNA), neurological disorders (LSDiASD), ageing biology (RNAging), and immunotherapy (ITHACA), suggesting they provide commercialization expertise rather than domain-specific research. The "TT" in their name likely reflects their core function: bridging the gap between laboratory findings and market-ready applications.

What they specialise in

How they've shifted over time

TTFACTOR's H2020 activity spans 2015-2018 with a consistent focus on ERC Proof of Concept commercialization support. Early involvement centered on RNA-based therapeutics (DDRNA in 2015, LSDiASD in 2016), while later projects shifted toward ageing biology and immunotherapy (RNAging in 2017, ITHACA in 2018). There is no dramatic pivot — rather a steady broadening across biomedical subfields, reinforcing their role as a domain-agnostic commercialization partner for life science researchers.

TTFACTOR appears to have ceased H2020 activity after 2018; any future collaboration would need to verify their current operational status and focus areas.

How they like to work

TTFACTOR operates almost exclusively as a third-party contributor (3 of 4 projects), indicating they are brought in by lead researchers to provide specific commercialization or business development services. Their network is extremely narrow — just 3 unique partners in 1 country — suggesting they serve a small circle of trusted academic collaborators, likely within the Milan or broader Italian research ecosystem. This is consistent with a boutique consultancy model rather than a large-scale consortium player.

Very small network of 3 partners within a single country (Italy). This tight circle is typical of a specialized service provider embedded in a local academic ecosystem rather than a broadly networked organization.

What sets them apart

TTFACTOR occupies a niche as a dedicated ERC Proof of Concept commercialization partner in the Italian life science space. Unlike research institutes that contribute scientific expertise, they appear to bring business development, market assessment, or IP strategy to help academics translate findings into applications. For ERC grant holders in biomedical fields seeking third-party commercialization support, this focused positioning could be valuable — though their small footprint and inactivity since 2018 warrant due diligence.

Highlights from their portfolio

• LSDiASD
  Their only project as a named participant (not third party) and the sole project with recorded EC funding (EUR 37,500), focused on a specific therapeutic target for autism spectrum disorder.
• ITHACA
  Their most recent project (2018-2019), combining immunotherapy with phage display for acute myeloid leukemia — a high-value therapeutic area with strong commercial potential.